HLB Therapeutics Co.,Ltd.: debt-to-equity, ROE and more
KOSDAQ, Legal name HLB Therapeutics Co.,Ltd.
Latest figures are the FY2025 consolidated summary statements.
Latest fiscal year ratios (computed here)
- Debt/equity
- 31.5%
- Equity ratio
- 76.0%
- ROE
- -5.6%
- Op. margin
- -5.1%
- Rev. growth
- 26.6%
- Interest coverage
- n/a
Condition flags
- Latest operating profit is not above zero, or not reported.
- Operating loss for 5 straight years.
- Total equity is above paid-in capital. Not capital-impaired.
Interest coverage and dividends (OpenDART)
Interest expense and dividends come from DART's OpenDART annual-report filings, not the FSC summary statements used above. The source differs from the other tables on this page.
Interest coverage = operating profit ÷ interest expenseNo interest expense value yet for this company. Most companies fold interest expense into a single finance-costs line on their income statement, so it cannot be pulled out separately. Interest coverage is not computed here.
Dividends, last 3 fiscal years
No dividend data yet for this company.
Source values from the OpenDART (금융감독원 전자공시) annual report. Report fiscal year 2025.
Ratios by year (computed here)
Debt-to-equity = total liabilities ÷ total equity × 100Equity ratio = total equity ÷ total assets × 100ROE = net income ÷ year-end total equity × 100Operating margin = operating profit ÷ revenue × 100Revenue growth = (this year − last year) ÷ last year × 100
Computed from the source figures above with these formulas. Where the source's own debt-to-equity differs from ours, both are shown for that year.
| Fiscal year | Debt/equity | Equity ratio | ROE | Op. margin | Rev. growth |
|---|---|---|---|---|---|
| FY2021 consolidated | 45.9% | 68.5% | -13.7% | -25.4% | n/a |
| FY2022 consolidated | 46.5% | 68.3% | -9.4% | -16.4% | 10.4% |
| FY2023 consolidated | 17.1% | 85.4% | -1.8% | -16.2% | 11.7% |
| FY2024 consolidated | 20.9% | 82.7% | -12.9% | -13.9% | 2.2% |
| FY2025 consolidated | 31.5% | 76.0% | -5.6% | -5.1% | 26.6% |
Source figures (FSC summary statements)
Amounts are the source values, shortened. A cell reported as zero may be blank in the source, so it is not used in any ratio.
| Fiscal year | 2021 | 2022 | 2023 | 2024 | 2025 |
|---|---|---|---|---|---|
| Revenue | ₩43.6B | ₩48.1B | ₩53.7B | ₩54.9B | ₩69.6B |
| Operating profit | -₩11.1B | -₩7.9B | -₩8.7B | -₩7.6B | -₩3.5B |
| Pre-tax income | -₩17.8B | -₩12.1B | -₩2.8B | -₩22.9B | -₩11.1B |
| Net income | -₩17.8B | -₩12.1B | -₩3.1B | -₩23.5B | -₩9.7B |
| Total assets | ₩189.7B | ₩187.6B | ₩200.8B | ₩219.8B | ₩228.7B |
| Total liabilities | ₩59.7B | ₩59.5B | ₩29.3B | ₩37.9B | ₩54.8B |
| Total equity | ₩130.0B | ₩128.1B | ₩171.5B | ₩181.9B | ₩173.9B |
| Paid-in capital | ₩15.7B | ₩16.0B | ₩37.0B | ₩40.1B | ₩42.2B |
| Debt/equity (source value) | 45.9% | 46.5% | 17.1% | 20.9% | 31.5% |
Company outline (FSC)
- Market
- KOSDAQ
- Fiscal year end
- Dec
- Founded
- 2000-06-07
- Listed
- 10/03/26
- Employees
- 50
- Auditor
- 삼정회계법인
- Audit opinion
- 적정의견
- Corporate reg. no.
- 1601110099451
- Outline updated
- 2026-09-24
Check the original filings
Read the annual report and audit report before you decide anything. The link opens a DART search for this company's name.
Search DART for HLB테라퓨틱스Computed from the Financial Services Commission's company outline and summary statements (data.go.kr). Data as of 2026-09-24.